A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Active:	Yes
Cancer Type:	Prostate Cancer Unknown Primary	NCT ID:	NCT06842498
Trial Phases:	Phase II	Protocol IDs:	FGCL-3246-112 (primary) NCI-2025-01692
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Kyntra Bio
NCI Full Details:	http://clinicaltrials.gov/show/NCT06842498

Summary

The purpose of this study is to evaluate the safety, efficacy, tolerability, and
pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting
antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have
progressed following treatment with one prior second-generation androgen receptor
signaling inhibitor (ARSI) in any setting and no prior taxane therapy in the mCRPC
setting.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.